MAPT and Alzheimer disease: The commonly used AD molecular biomarkers include increased tau protein and amyloid beta peptide (Aβ42) levels and tau hyperphosphorylation in cerebrospinal fluid (CSF), as well as amyloid beta lesions in brain, the latter detected by positron emission tomography19.